Atrium Therapeutics earns $15M milestone from Bristol Myers Squibb for heart RNA therapy progress

Atrium Therapeutics received a $15 million milestone payment from Bristol Myers Squibb after successfully delivering a development candidate for a heart-targeted RNA therapy under their collaboration. This milestone advances Atrium's RNA delivery platform aimed at treating genetic cardiac diseases, with potential therapies for rare cardiomyopathies like PRKAG2 syndrome and PLN cardiomyopathy. Bristol Myers Squibb will fund further clinical development and commercialization, with Atrium eligible for up to $2.175 billion in milestones and royalties. This collaboration highlights progress in innovative RNA treatments for heart conditions with no current approved therapies addressing underlying genetic causes.